ArticleOpen forum infectious diseases2026
Epidemiology of HMPV and Other Respiratory Viral Infections Among Outpatients, 2016-2022.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Most studies of human metapneumovirus (HMPV) epidemiology have been among inpatients. This study examined the epidemiology of HMPV compared with other common viruses among outpatients seeking care for an acute respiratory illness (ARI) during 5 influenza seasons (2016-2017 to 2019-2020, before the coronavirus disease 2019 pandemic, and in 2021-2022, during the pandemic). Methods: Outpatients ≥6 months old seeking care for ARI and presenting with cough of ≤7 days' duration provided nasal and pharyngeal swab samples, demographic data, and access to electronic medical record data. Samples were tested with reverse-transcription polymerase chain reaction assays for HMPV, influenza, parainfluenza virus (PIV) 1-4, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Student's Results: After exclusion of 68 coinfections, 7143 patients remained; 2017 had influenza, 762 had RSV, 423 had HMPV, 83 had PIV, 352 had SARS-CoV-2, and 3506 tested polymerase chain reaction negative for all of these viruses. Of all patients with ARI each influenza season, 30.2%-37.1% tested positive for influenza, 11.3%-13.6% for RSV, 4.7%-7.3% for HMPV, and 0.1%-1.9% for PIV. Compared with patients with RSV, those with HMPV less often had congestion, dyspnea, and sore throat. Compared with patients with influenza, those with HMPV were less likely to have fever but more often had congestion or dyspnea and felt worse at 7-14-day follow-up. Children recovered from HMPV faster than adults. Conclusions: HMPV is an important cause of outpatient ARI during influenza season. Patients with HMPV had slightly different demographic characteristics and symptoms from those with other ARIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.